SCHOTT to invest in China

This week, the company has laid the cornerstone for another pharmaceutical packaging plant that will be located south of Shanghai. Starting in 2017, glass packaging for injectable drugs will be manufactured here, in particular vials and ampoules. Furthermore, the SCHOTT Group also plans to modernize and expand its existing facilities at its integrated site in Suzhou. The Pharmaceutical Systems division of SCHOTT will invest approx. EUR 30 million in total in China over the next three years. These measures will increase the company’s production capacity by 50 per cent over the same period.



With this expansion, the company is paying tribute to the strong growth of the Chinese pharmaceutical market. SCHOTT serves this market from two production facilities – a plant in Suzhou, which is an integrated production facility of the SCHOTT Group, and through its joint venture, Zhejiang Xinkang Pharmaceutical Glass Co. The new production facility will be built at the site of Xinkang’s headquarters in Jinyun.



SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of 1.87 billion euros were generated in fiscal year 2013/2014. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment. www.schott.com